<DOC>
	<DOCNO>NCT02625090</DOCNO>
	<brief_summary>The purpose study EP0073 ass long-term safety , tolerability , efficacy 5 year treatment drug UCB0942 patient highly drug-resistant focal epilepsy . Also , effect UCB0942 patient 's quality life explore .</brief_summary>
	<brief_title>An Open-label Extension Study UCB0942 Adult Patients With Highly Drug-resistant Focal Epilepsy</brief_title>
	<detailed_description>For subject benefit substantially UCB0942 multicenter , randomize , double-blind placebo-controlled , parallel group study EP0069 , current open-label extension study EP0073 provide opportunity continue UCB0942 treatment careful evaluation individual benefit-risk balance close monitoring safety , tolerability efficacy long-term study treatment .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<criteria>A write Informed Consent form approve Independent Ethics Committee sign date subject , Investigator assess whether subject able understand potential risk benefit participate study Subject must complete Visit 13 ( V13 ) Outpatient Maintenance Period EP0069 eligible enrollment EP0073 In EP0069 , subject demonstrate reduction frequency and/or severity seizure compare baseline consider clinically significant Investigator significant subject In EP0069 , subject experience substantial benefit UCB0942 acceptable tolerability accord subject Investigator No tolerability issue outweigh attain benefit , opinion Investigator Female subject nonchildbearing potential ( premenarcheal , postmenopausal least 2 year , bilateral oophorectomy tubal ligation , complete hysterectomy ) eligible . Female subject childbearing potential eligible use medically accept contraceptive method . Male subject confirms , study period period 3 month final dose , sexual intercourse woman childbearing potential , use barrier contraceptive ( eg , condom ) AND respective partner use additional contraceptive method Subject active suicidal ideation indicate positive response ( `` Yes '' ) either Question 4 Question 5 `` Since Last Visit '' version Columbia Suicide Severity Rating Scale . The subject refer immediately Mental Healthcare Professional must withdraw study Subject take ( nonAntiEpileptic Drug ) prescription , nonprescription , dietary ( eg , grapefruit passion fruit ) , herbal product potent inducer inhibitor CYP3A4 pathway 2 week ( 5 half life whichever longer ) prior study entry Subject abnormality 12lead electrocardiography , opinion Investigator , increase risk associate participate study . In addition , subject follow finding exclude : Prolonged QTc ( Bazett 's , machineread ) interval define &gt; 450 m male &gt; 470 m female Bundle branch block conduction abnormality mild first degree atrioventricular block ( define PR interval ≥ 220 m ) Irregular rhythm sinus arrhythmia occasional , rare supraventricular rare ventricular ectopic beat In judgment Investigator , Twave configuration sufficient quality assess QT interval duration • Subject clinically significant abnormality echocardiography Entry Visit ( V2 ) EP0073</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Drug-resistance</keyword>
	<keyword>focal epilepsy</keyword>
	<keyword>partial-onset seizure</keyword>
</DOC>